Indivior Pharmaceuticals Inc. (INDV) could be a solid choice for shorter-term investors looking to c

Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook art

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may pr

Barclays analyst Glen Santangelo initiates coverage on Indivior Pharmaceuticals (NASDAQ:INDV) wit

Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent

Indivior Pharmaceuticals, Inc. (NASDAQ:INDV), today announced that it has entered into a $175 millio

Indivior Pharmaceuticals (NASDAQ:INDV) raises FY2026 sales outlook from $1.125 billion-$1.195 billio

Indivior (NASDAQ:INDV) reported quarterly earnings of $0.96 per share which beat the analyst consens

https://sam.gov/opp/301d35fe03404ac6ad3aec2215c3c893/view

Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to mar

Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. thos

Indivior Pharmaceuticals (NASDAQ:INDV) affirms FY2026 sales outlook from $1.125 billion-$1.195 billi

Indivior (NASDAQ:INDV) reported quarterly earnings of $0.82 per share which beat the analyst consens

Kevin Mahn highlighted the potential impact of the recent tariff noise on the market and advised inv

HC Wainwright & Co. analyst Brandon Folkes maintains Indivior (NASDAQ:INDV) with a Buy and ra

Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerate

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20251205-1480992/1480992_decembe

Indivior PLC (Nasdaq: INDV) presented three new scientific posters at the Academy of Managed Care Ph

Piper Sandler analyst David Amsellem reiterates Indivior (NASDAQ:INDV) with a Overweight and rais

HC Wainwright & Co. analyst Brandon Folkes maintains Indivior (NASDAQ:INDV) with a Buy and ra

Indivior (NASDAQ:INDV) raises FY2025 sales outlook from $1.030 billion-$1.080 billion to $1.180 bill

Indivior (NASDAQ:INDV) reported quarterly earnings of $0.72 per share which beat the analyst consens

Rapid induction with SUBLOCADE® showed higher treatment retention rates compared to standard inducti

Craig-Hallum analyst Chase Knickerbocker maintains Indivior (NASDAQ:INDV) with a Buy and raises t

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Indivior (NASDAQ:INDV) with

Indivior (NASDAQ:INDV) raises FY2025 sales outlook from $955.000 million-$1.025 billion to $1.030 bi

Indivior (NASDAQ:INDV) reported quarterly earnings of $0.51 per share which beat the analyst consens

Jefferies analyst Dennis Ding assumes Indivior (NASDAQ:INDV) with a Buy rating and announces Pric

Craig-Hallum analyst Chase Knickerbocker maintains Indivior (NASDAQ:INDV) with a Buy and raises t

A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine e

In further consideration of Indivior's listing structure, the Board now believes that the London

Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for subs

Shares of Etsy, Inc.

U.S. stocks were higher, with the Nasdaq Composite gaining more 2% on Thursday.

Shares of NVIDIA Corporation (NASDAQ: NVDA) rose sharply in today’s pre-market trading after the co

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings